Wiktor Daniszewski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wiktor Daniszewski has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Bartosz Oder
Pomeranian Medical University In Szczecin, Szczecin, Poland
1 shared publication - Dominika Pietrzyk
Pediatric, Adolescent Gynecology Clinic, Department of Gynecology, Endocrinology and Gynecological Oncology, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland
1 shared publication - Gabriela Furtak
Department of Reconstructive Surgery and Gynecological Oncology, Pomeranian Medical University in Szczecin, Powstańców Wielkopolskich 72, 70-111 Szczecin, Poland
1 shared publication - Katarzyna Zając
Pediatric, Adolescent Gynecology Clinic, Department of Gynecology, Endocrinology and Gynecological Oncology, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland
1 shared publication - Maciej Ćmil
Department of Physiology, Pomeranian Medical University, 70-111 Szczecin, Poland
1 shared publication - Maria Łagódka
Hospital in Puszczykowo, Puszczykowo, Poland
1 shared publication
Latest Publications
- Open Access
- 2 December 2025
- Published by Asosiasi Asesmen Pendidikan (AAP) in JITSS (Journal of Innovation and Trend in Social Sciences)
- Vol. 2 (2) , 87-100
Systemic Effects of Phosphodiesterase Type 5 Inhibitors Beyond Erectile Dysfunction: A Narrative Review
Phosphodiesterase type 5 inhibitors (PDE5Is) are widely prescribed for erectile dysfunction; however, growing evidence indicates that their pharmacological effects extend beyond urological indications and involve multiple organ systems. This narrative review aims to synthesize and critically evaluate current evidence on the systemic effects of PDE5 inhibitors across cardiovascular, renal, neurological, and urological domains, as well as emerging therapeutic indications. A comprehensive literature search was conducted using PubMed, Scopus, and Web of Science for studies published up to May 2024, including preclinical studies, clinical trials, observational studies, systematic reviews, and meta-analyses. The reviewed evidence demonstrates that PDE5 inhibitors are associated with reduced cardiovascular morbidity and mortality, improvements in cardiac and pulmonary hemodynamics, preservation of renal function in diabetic populations, potential neuroprotective effects against cognitive decline and ischemic stroke, and symptomatic improvement in benign prostatic hyperplasia and lower urinary tract symptoms. Additional benefits have been reported in conditions characterized by vascular dysfunction, such as angina pectoris and Raynaud’s phenomenon. Overall, PDE5 inhibitors represent a pharmacologically versatile drug class with clinically relevant systemic effects beyond erectile dysfunction, supporting their potential role as adjunctive therapies in broader disease management, although further well-designed randomized controlled trials are needed to inform clinical guidelines.
- 2 December 2025
- Published by Asosiasi Asesmen Pendidikan (AAP) in JITSS (Journal of Innovation and Trend in Social Sciences)
- Vol. 2 (2) , 87-100
Open AccessSystemic Effects of Phosphodiesterase Type 5 Inhibitors Beyond Erectile Dysfunction: A Narrative Review
Phosphodiesterase type 5 inhibitors (PDE5Is) are widely prescribed for erectile dysfunction; however, growing evidence indicates that their pharmacological effects extend beyond urological indications and involve multiple organ systems. This narrative review aims to synthesize and critically evaluate current evidence on the systemic effects of PDE5 inhibitors across cardiovascular, renal, neurological, and urological domains, as well as emerging therapeutic indications. A comprehensive literature search was conducted using PubMed, Scopus, and Web of Science for studies published up to May 2024, including preclinical studies, clinical trials, observational studies, systematic reviews, and meta-analyses. The reviewed evidence demonstrates that PDE5 inhibitors are associated with reduced cardiovascular morbidity and mortality, improvements in cardiac and pulmonary hemodynamics, preservation of renal function in diabetic populations, potential neuroprotective effects against cognitive decline and ischemic stroke, and symptomatic improvement in benign prostatic hyperplasia and lower urinary tract symptoms. Additional benefits have been reported in conditions characterized by vascular dysfunction, such as angina pectoris and Raynaud’s phenomenon. Overall, PDE5 inhibitors represent a pharmacologically versatile drug class with clinically relevant systemic effects beyond erectile dysfunction, supporting their potential role as adjunctive therapies in broader disease management, although further well-designed randomized controlled trials are needed to inform clinical guidelines.